Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420797 | 0.85 | EPHX2 (0.45) | ALOX5ABL1 | |
| SCHEMBL24755064 | 0.85 | EPHX2 (0.45) | ALOX5ABL1 | |
| SCHEMBL22931766 | 0.83 | EPHX2 (0.45) | — | |
| SCHEMBL24756279 | 0.78 | JAK2 (0.37) | — | |
| SCHEMBL24756238 | 0.78 | DHODH (0.46) | ALDH1A1ABL1 | |
| SCHEMBL29420804 | 0.78 | DHODH (0.46) | ALDH1A1ABL1 | |
| SCHEMBL22932334 | 0.78 | ULK1 (0.33) | ALDH1A1ABL1 | |
| SCHEMBL24754842 | 0.78 | MEN1 (0.47) | ALDH1A1 | |
| SCHEMBL24754838 | 0.78 | GRM4 (0.46) | ALDH1A1 | |
| SCHEMBL29420790 | 0.78 | ULK1 (0.33) | ALDH1A1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| EP-4003983-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | ALOX5 527/4885ALDH1A1 559/4885ABL1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.